CD79A and diffuse large B-cell lymphoma: Similarly to DLBCL, the immunophenotype is characterized by the expression of CD45, of B-cell antigens CD20 and CD79a and transcription factors PAX5, BOB1 and OCT2, but is also associated to CHL markers CD30 and CD15 positivity.33 Sometimes a neoplasia resembling morphologically a PMBL but negative for CD20 can occur; in this instances a diagnosis of lymphoma with intermediate features between CHL and DLBCL can be made, if supported by CD15 and/or EBV positivity.33